Last reviewed · How we verify
ABBV-552
ABBV-552 is a small molecule inhibitor of the sphingosine-1-phosphate receptor 1 (S1PR1).
ABBV-552 is a small molecule inhibitor of the sphingosine-1-phosphate receptor 1 (S1PR1). Used for Moderate to severe multiple sclerosis.
At a glance
| Generic name | ABBV-552 |
|---|---|
| Sponsor | AbbVie |
| Drug class | S1PR1 inhibitor |
| Target | S1PR1 |
| Modality | Small molecule |
| Therapeutic area | Autoimmune diseases |
| Phase | Phase 2 |
Mechanism of action
By blocking S1PR1, ABBV-552 aims to reduce inflammation and modulate immune responses. This mechanism is being explored for its potential in treating autoimmune diseases.
Approved indications
- Moderate to severe multiple sclerosis
Common side effects
- Headache
- Nausea
- Diarrhea
Key clinical trials
- Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease (PHASE2)
- A Study to Assess the Mass Balance of [14C] ABBV-552 in Healthy Male Participants Following Single Oral Dose Administration (PHASE1)
- A Study to Assess the Adverse Events and How Oral ABBV-552 Capsules Moves Through the Body of Healthy Adult Japanese and Han Chinese Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |